Search

Displaying results 4661 - 4670 of 5925 in total
  1. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    Due to its pharmacological properties, it can be administered intranasally.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Nizubaglustat

    go.drugbank.com/drugs/DB21603
    Investigational

    Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

  3. Drug

    Vicadrostat

    go.drugbank.com/drugs/DB21693
    Investigational

    Vicadrostat has a monoisotopic molecular weight of 317.06 Da.

  4. Drug

    Dichlorvos

    go.drugbank.com/drugs/DB11397
    ExperimentalVet approved

    The compound has been available on the market since 1961 and its use is a controversial topic due to environmental and health concerns.

  5. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.

  6. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    Rivanicline also has stimulant and analgesic actions which are thought due to increased noradrenaline release.

  7. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do

  8. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as … human pooled blood and contains both A- and B-subunits, and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared with conventional factor VIII due

    Products: Xyntha 250 IU Powder and Solvent for Solution for Injection, Xyntha 1000 IU Powder and Solvent for Solution for Injection
  9. Drug

    Prolgolimab

    go.drugbank.com/drugs/DB16740
    Investigational

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  10. Drug

    Tetrahydropalmatine

    go.drugbank.com/drugs/DB12093
    Investigational

    Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).

    Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 Substrates